UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY

Home

Download

Statistics

Examples

Help

Contact

	Kinase Fusion Gene Summary
	Kinase Fusion Gene Sample Information
	Kinase Fusion ORF Analysis
	Kinase Fusion Amino Acid Sequences
	Multiple Sequence Alignment of All Fusion Protein Isoforms
	Kinase Fusion Protein Functional Features
	Kinase Fusion Protein Structures
	Comparison of Fusion Protein Isoforms
	Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB
	pLDDT Scores and Difference Analysis of pLDDT Scores Between the Active Sites (Best) and Non-Active Sites.
	Ramachandran Plot of Kinase Fusion Protein Structure
	Potential Active Site Information
	Virtual Screening Results
	Kinase-Substrate Information
	Related Drugs with This Kinase Fusion Protein
	Related Disease with This Kinase Fusion Protein
	Clinical Trials of the Found Drugs/Small Molecules

Kinase Fusion Gene:OBSCN_KCNK2

Kinase Fusion Protein Summary

Kinase Fusion gene summary

Kinase Fusion partner gene information	Kinase Fusion gene name: OBSCN_KCNK2
	KinaseFusionDB ID: KFG4340
	FusionGDB2.0 ID: KFG4340
		Hgene	Tgene
	Gene symbol	OBSCN	KCNK2
	Gene ID	84033	3776
	Gene name	obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF	potassium two pore domain channel subfamily K member 2
	Synonyms	ARHGEF30\|RHABDO1\|UNC89	K2p2.1\|TPKC1\|TREK\|TREK-1\|TREK1\|hTREK-1c\|hTREK-1e
	Cytomap	1q42.13	1q41
	Type of gene	protein-coding	protein-coding
	Description	obscurinobscurin, myosin light chain kinaseobscurin-MLCK	potassium channel subfamily K member 2K2P2.1 potassium channelTREK-1 K(+) channel subunitTWIK-related potassium channel 1outward rectifying potassium channel protein TREK-1potassium channel, two pore domain subfamily K, member 2potassium inwardly-re
	Modification date	20240407	20240305
	UniProtAcc	Q5VST9	Q13303
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000284548, ENST00000366707, ENST00000366709, ENST00000422127, ENST00000570156, ENST00000359599, ENST00000602685,	ENST00000391894, ENST00000391895, ENST00000444842,
Context (manual curation of fusion genes in KinaseFusionDB)	PubMed: OBSCN [Title/Abstract] AND KCNK2 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	OBSCN(228525084)-KCNK2(215368296), # samples:3

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Kinase Fusion gene breakpoints across OBSCN (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Kinase Fusion gene breakpoints across KCNK2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Kinase Fusion Gene Sample Information

Kinase Fusion gene information.

Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Sample	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp
ChimerDB4	TCGA-YD-A89C-06A	OBSCN	chr1	228525084	KCNK2	chr1	215368296
ChimerDB4	TCGA-YD-A89C-06A	OBSCN	chr1	228524827	KCNK2	chr1	215368296

Top

Kinase Fusion ORF Analysis

Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB.

Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Seq length (transcript)	Seq length (amino acids)
ENST00000284548	ENST00000391895	OBSCN	chr1	228524827	KCNK2	chr1	215368296	17266	5705

Top

Kinase Fusion Amino Acid Sequences

For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq

>ENST00000284548_ENST00000391895_OBSCN_chr1_228524827_KCNK2_chr1_215368296_length(amino acids)=5705
MDQPQFSGAPRFLTRPKAFVVSVGKDATLSCQIVGNPTPQVSWEKDQQPVAAGARFRLAQDGDLYRLTILDLALGDSGQYVCRARNAIGE
AFAAVGLQVDAEAACAEQAPHFLLRPTSIRVREGSEATFRCRVGGSPRPAVSWSKDGRRLGEPDGPRVRVEELGEASALRIRAARPRDGG
TYEVRAENPLGAASAAAALVVDSDAADTASRPGTSTAALLAHLQRRREAMRAEGAPASPPSTGTRTCTVTEGKHARLSCYVTGEPKPETV
WKKDGQLVTEGRRHVVYEDAQENFVLKILFCKQSDRGLYTCTASNLVGQTYSSVLVVVREPAVPFKKRLQDLEVREKESATFLCEVPQPS
TEAAWFKEETRLWASAKYGIEEEGTERRLTVRNVSADDDAVYICETPEGSRTVAELAVQGNLLRKLPRKTAVRVGDTAMFCVELAVPVGP
VHWLRNQEEVVAGGRVAISAEGTRHTLTISQCCLEDVGQVAFMAGDCQTSTQFCVSAPRKPPLQPPVDPVVKARMESSVILSWSPPPHGE
RPVTIDGYLVEKKKLGTYTWIRCHEAEWVATPELTVADVAEEGNFQFRVSALNSFGQSPYLEFPGTVHLAPKLAVRTPLKAVQAVEGGEV
TFSVDLTVASAGEWFLDGQALKASSVYEIHCDRTRHTLTIREVPASLHGAQLKFVANGIESSIRMEVRAAPGLTANKPPAAAAREVLARL
HEEAQLLAELSDQAAAVTWLKDGRTLSPGPKYEVQASAGRRVLLVRDVARDDAGLYECVSRGGRIAYQLSVQGLARFLHKDMAGSCVDAV
AGGPAQFECETSEAHVHVHWYKDGMELGHSGERFLQEDVGTRHRLVAATVTRQDEGTYSCRVGEDSVDFRLRVSEPKVVFAKEQLARRKL
QAEAGASATLSCEVAQAQTEVTWYKDGKKLSSSSKVCMEATGCTRRLVVQQAGQADAGEYSCEAGGQRLSFHLDVKEPKVVFAKDQVAHS
EVQAEAGASATLSCEVAQAQTEVMWYKDGKKLSSSLKVHVEAKGCRRRLVVQQAGKTDAGDYSCEARGQRVSFRLHITEPKMMFAKEQSV
HNEVQAEAGASAMLSCEVAQAQTEVTWYKDGKKLSSSSKVGMEVKGCTRRLVLPQAGKADAGEYSCEAGGQRVSFHLHITEPKGVFAKEQ
SVHNEVQAEAGTTAMLSCEVAQPQTEVTWYKDGKKLSSSSKVRMEVKGCTRRLVVQQVGKADAGEYSCEAGGQRVSFQLHITEPKAVFAK
EQLVHNEVRTEAGASATLSCEVAQAQTEVTWYKDGKKLSSSSKVRIEAAGCMRQLVVQQAGQADAGEYTCEAGGQRLSFHLDVSEPKAVF
AKEQLAHRKVQAEAGAIATLSCEVAQAQTEVTWYKDGKKLSSSSKVRMEAVGCTRRLVVQQACQADTGEYSCEAGGQRLSFSLDVAEPKV
VFAKEQPVHREVQAQAGASTTLSCEVAQAQTEVMWYKDGKKLSFSSKVRMEAVGCTRRLVVQQAGQAVAGEYSCEAGSQRLSFHLHVAEP
KAVFAKEQPASREVQAEAGTSATLSCEVAQAQTEVTWYKDGKKLSSSSKVRMEAVGCTRRLVVQEAGQADAGEYSCKAGDQRLSFHLHVA
EPKVVFAKEQPAHREVQAEAGASATLSCEVAQAQTEVTWYKDGKKLSSSSKVRVEAVGCTRRLVVQQAGQAEAGEYSCEAGGQQLSFRLQ
VAELEPQISERPCRREPLVVKEHEDIILTATLATPSAATVTWLKDGVEIRRSKRHETASQGDTHTLTVHGAQVLDSAIYSCRVGAEGQDF
PVQVEEVAAKFCRLLEPVCGELGGTVTLACELSPACAEVVWRCGNTQLRVGKRFQMVAEGPVRSLTVLGLRAEDAGEYVCESRDDHTSAQ
LTVSVPRVVKFMSGLSTVVAEEGGEATFQCVVSPSDVAVVWFRDGALLQPSEKFAISQSGASHSLTISDLVLEDAGQITVEAEGASSSAA
LRVREAPVLFKKKLEPQTVEERSSVTLEVELTRPWPELRWTRNATALAPGKNVEIHAEGARHRLVLHNVGFADRGFFGCETPDDKTQAKL
TVEMRQVRLVRGLQAVEAREQGTATMEVQLSHADVDGSWTRDGLRFQQGPTCHLAVRGPMHTLTLSGLRPEDSGLMVFKAEGVHTSARLV
VTELPVSFSRPLQDVVTTEKEKVTLECELSRPNVDVRWLKDGVELRAGKTMAIAAQGACRSLTIYRCEFADQGVYVCDAHDAQSSASVKV
QGRTYTLIYRRVLAEDAGEIQFVAENAESRAQLRVKELPVTLVRPLRDKIAMEKHRGVLECQVSRASAQVRWFKGSQELQPGPKYELVSD
GLYRKLIISDVHAEDEDTYTCDAGDVKTSAQFFVEEQSITIVRGLQDVTVMEPAPAWFECETSIPSVRPPKWLLGKTVLQAGGNVGLEQE
GTVHRLMLRRTCSTMTGPVHFTVGKSRSSARLVVSDIPVVLTRPLEPKTGRELQSVVLSCDFRPAPKAVQWYKDDTPLSPSEKFKMSLEG
QMAELRILRLMPADAGVYRCQAGSAHSSTEVTVEAREVTVTGPLQDAEATEEGWASFSCELSHEDEEVEWSLNGMPLYNDSFHEISHKGR
RHTLVLKSIQRADAGIVRASSLKVSTSARLEVRVKPVVFLKALDDLSAEERGTLALQCEVSDPEAHVVWRKDGVQLGPSDKYDFLHTAGT
RGLVVHDVSPEDAGLYTCHVGSEETRARVRVHDLHVGITKRLKTMEVLEGESCSFECVLSHESASDPAMWTVGGKTVGSSSRFQATRQGR
KYILVVREAAPSDAGEVVFSVRGLTSKASLIVRERPAAIIKPLEDQWVAPGEDVELRCELSRAGTPVHWLKDRKAIRKSQKYDVVCEGTM
AMLVIRGASLKDAGEYTCEVEASKSTASLHVEEKANCFTEELTNLQVEEKGTAVFTCKTEHPAATVTWRKGLLELRASGKHQPSQEGLTL
RLTISALEKADSDTYTCDIGQAQSRAQLLVQGRRVHIIEDLEDVDVQEGSSATFRCRISPANYEPVHWFLDKTPLHANELNEIDAQPGGY
HVLTLRQLALKDSGTIYFEAGDQRASAALRVTEKPSVFSRELTDATITEGEDLTLVCETSTCDIPVCWTKDGKTLRGSARCQLSHEGHRA
QLLITGATLQDSGRYKCEAGGACSSSIVRVHARPVRFQEALKDLEVLEGGAATLRCVLSSVAAPVKWCYGNNVLRPGDKYSLRQEGAMLE
LVVRNLRPQDSGRYSCSFGDQTTSATLTVTALPAQFIGKLRNKEATEGATATLRCELSKAAPVEWRKGSETLRDGDRYCLRQDGAMCELQ
IRGLAMVDAAEYSCVCGEERTSASLTIRPMPAHFIGRLRHQESIEGATATLRCELSKAAPVEWRKGRESLRDGDRHSLRQDGAVCELQIC
GLAVADAGEYSCVCGEERTSATLTVKALPAKFTEGLRNEEAVEGATAMLWCELSKVAPVEWRKGPENLRDGDRYILRQEGTRCELQICGL
AMADAGEYLCVCGQERTSATLTIRALPARFIEDVKNQEAREGATAVLQCELNSAAPVEWRKGSETLRDGDRYSLRQDGTKCELQIRGLAM
ADTGEYSCVCGQERTSAMLTVRALPIKFTEGLRNEEATEGATAVLRCELSKMAPVEWWKGHETLRDGDRHSLRQDGARCELQIRGLVAED
AGEYLCMCGKERTSAMLTVRAMPSKFIEGLRNEEATEGDTATLWCELSKAAPVEWRKGHETLRDGDRHSLRQDGSRCELQIRGLAVVDAG
EYSCVCGQERTSATLTVRALPARFIEDVKNQEAREGATAVLQCELSKAAPVEWRKGSETLRGGDRYSLRQDGTRCELQIHGLSVADTGEY
SCVCGQERTSATLTVRAPQPVFREPLQSLQAEEGSTATLQCELSEPTATVVWSKGGLQLQANGRREPRLQGCTAELVLQDLQREDTGEYT
CTCGSQATSATLTVTAAPVRFLRELQHQEVDEGGTAHLCCELSRAGASVEWRKGSLQLFPCAKYQMVQDGAAAELLVRGVEQEDAGDYTC
DTGHTQSMASLSVRVPRPKFKTRLQSLEQETGDIARLCCQLSDAESGAVVQWLKEGVELHAGPKYEMRSQGATRELLIHQLEAKDTGEYA
CVTGGQKTAASLRVTEPEVTIVRGLVDAEVTADEDVEFSCEVSRAGATGVQWCLQGLPLQSNEVTEVAVRDGRIHTLRLKGVTPEDAGTV
SFHLGNHASSAQLTVRAPEVTILEPLQDVQLSEGQDASFQCRLSRASGQEARWALGGVPLQANEMNDITVEQGTLHLLTLHKVTLEDAGT
VSFHVGTCSSEAQLKVTAKNTVVRGLENVEALEGGEALFECQLSQPEVAAHTWLLDDEPVHTSENAEVVFFENGLRHLLLLKNLRPQDSC
RVTFLAGDMVTSAFLTVRGWRLEILEPLKNAAVRAGAQACFTCTLSEAVPVGEASWYINGAAVQPDDSDWTVTADGSHHALLLRSAQPHH
AGEVTFACRDAVASARLTVLGLPDPPEDAEVVARSSHTVTLSWAAPMSDGGGGLCGYRVEVKEGATGQWRLCHELVPGPECVVDGLAPGE
TYRFRVAAVGPVGAGEPVHLPQTVRLAEPPKPVPPQPSAPESRQVAAGEDVSLELEVVAEAGEVIWHKGMERIQPGGRFEVVSQGRQQML
VIKGFTAEDQGEYHCGLAQGSICPAAATFQVALSPASVDEAPQPSLPPEAAQEGDLHLLWEALARKRRMSREPTLDSISELPEEDGRSQR
LPQEAEEVAPDLSEGYSTADELARTGDADLSHTSSDDESRAGTPSLVTYLKKAGRPGTSPLASKVGAPAAPSVKPQQQQEPLAAVRPPLG
DLSTKDLGDPSMDKAAVKIQAAFKGYKVRKEMKQQEGPMFSHTFGDTEAQVGDALRLECVVASKADVRARWLKDGVELTDGRHHHIDQLG
DGTCSLLITGLDRADAGCYTCQVSNKFGQVTHSACVVVSGSESEAESSSGGELDDAFRRAARRLHRLFRTKSPAEVSDEELFLSADEGPA
EPEEPADWQTYREDEHFICIRFEALTEARQAVTRFQEMFATLGIGVEIKLVEQGPRRVEMCISKETPAPVVPPEPLPSLLTSDAAPVFLT
ELQNQEVQDGYPVSFDCVVTGQPMPSVRWFKDGKLLEEDDHYMINEDQQGGHQLIITAVVPADMGVYRCLAENSMGVSSTKAELRVDLTS
TDYDTAADATESSSYFSAQGYLSSREQEGTESTTDEGQLPQVVEELRDLQVAPGTRLAKFQLKVKGYPAPRLYWFKDGQPLTASAHIRMT
DKKILHTLEIISVTREDSGQYAAYISNAMGAAYSSARLLVRGPDEPEEKPASDVHEQLVPPRMLERFTPKKVKKGSSITFSVKVEGRPVP
TVHWLREEAERGVLWIGPDTPGYTVASSAQQHSLVLLDVGRQHQGTYTCIASNAAGQALCSASLHVSGLPKVEEQEKVKEALISTFLQGT
TQAISAQGLETASFADLGGQRKEEPLAAKEALGHLSLAEVGTEEFLQKLTSQITEMVSAKITQGGSDIEYLDFYKPVVWFWILVGLAYFA
AVLSMIGDWLRVISKKTKEEVGEFRAHAAEWTANVTAEFKETRRRLSVEIYDKFQRATSIKRKLSAELAGNHNQELTPCRRTLSVNHLTS

--------------------------------------------------------------

Multiple Sequence Alignment of All Fusion Protein Isoforms

Top

Kinase Fusion Protein Functional Features

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:228525084/chr1:215368296)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
OBSCN Q5VST9	KCNK2 Q13303
FUNCTION: Structural component of striated muscles which plays a role in myofibrillogenesis. Probably involved in the assembly of myosin into sarcomeric A bands in striated muscle (PubMed:11448995, PubMed:16205939). Has serine/threonine protein kinase activity and phosphorylates N-cadherin CDH2 and sodium/potassium-transporting ATPase subunit ATP1B1 (By similarity). Binds (via the PH domain) strongly to phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), and to a lesser extent to phosphatidylinositol 3-phosphate (PtdIns(3)P), phosphatidylinositol 4-phosphate (PtdIns(4)P), phosphatidylinositol 5-phosphate (PtdIns(5)P) and phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) (PubMed:28826662). {ECO:0000250\|UniProtKB:A2AAJ9, ECO:0000269\|PubMed:11448995, ECO:0000269\|PubMed:16205939, ECO:0000269\|PubMed:28826662}.	FUNCTION: Cytoplasmic potassium channel subunit that modulates the characteristics of the channel-forming alpha-subunits (PubMed:7649300, PubMed:11825900). Contributes to the regulation of nerve signaling, and prevents neuronal hyperexcitability (By similarity). Promotes expression of the pore-forming alpha subunits at the cell membrane, and thereby increases channel activity (By similarity). Promotes potassium channel closure via a mechanism that does not involve physical obstruction of the channel pore (PubMed:7649300, PubMed:11825900). Promotes KCNA4 channel closure (PubMed:7649300, PubMed:11825900). Modulates the functional properties of KCNA5 (By similarity). Enhances KCNB2 channel activity (By similarity). Binds NADPH and has NADPH-dependent aldoketoreductase activity (By similarity). Has broad substrate specificity and can catalyze the reduction of methylglyoxal, 9,10-phenanthrenequinone, prostaglandin J2, 4-nitrobenzaldehyde, 4-nitroacetophenone and 4-oxo-trans-2-nonenal (in vitro) (By similarity). {ECO:0000250\|UniProtKB:P62482, ECO:0000250\|UniProtKB:P62483, ECO:0000269\|PubMed:11825900, ECO:0000269\|PubMed:7649300}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page
* Minus value of BPloci means that the break pointn is located before the CDS.

- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt).

55535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553555355535553

Partner	Hgeneene	Hbp	Tgeneene	Tbp	ENST	BPexon	TotalExon	Protein feature loci	BPloci	TotalLen	Feature	Note
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	515_612	1	7969	Domain	Note=Fibronectin type-III 1;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00316
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	515_612	1	6621	Domain	Note=Fibronectin type-III 1;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00316
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1731_1808	1	7969	Domain	Note=Fibronectin type-III 2;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00316
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1731_1808	1	6621	Domain	Note=Fibronectin type-III 2;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00316
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	4525_4619	1	7969	Domain	Note=Fibronectin type-III 3;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00316
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	4525_4619	1	6621	Domain	Note=Fibronectin type-III 3;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00316
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	10_100	1	7969	Domain	Note=Ig-like 1
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	10_100	1	6621	Domain	Note=Ig-like 1
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	978_1066	1	7969	Domain	Note=Ig-like 10
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	978_1066	1	6621	Domain	Note=Ig-like 10
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1070_1161	1	7969	Domain	Note=Ig-like 11
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1070_1161	1	6621	Domain	Note=Ig-like 11
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1162_1252	1	7969	Domain	Note=Ig-like 12
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1162_1252	1	6621	Domain	Note=Ig-like 12
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1254_1345	1	7969	Domain	Note=Ig-like 13
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1254_1345	1	6621	Domain	Note=Ig-like 13
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1346_1432	1	7969	Domain	Note=Ig-like 14
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1346_1432	1	6621	Domain	Note=Ig-like 14
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1438_1524	1	7969	Domain	Note=Ig-like 15
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1438_1524	1	6621	Domain	Note=Ig-like 15
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1530_1621	1	7969	Domain	Note=Ig-like 16
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1530_1621	1	6621	Domain	Note=Ig-like 16
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1622_1719	1	7969	Domain	Note=Ig-like 17
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1622_1719	1	6621	Domain	Note=Ig-like 17
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1809_1894	1	7969	Domain	Note=Ig-like 18
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1809_1894	1	6621	Domain	Note=Ig-like 18
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1896_1982	1	7969	Domain	Note=Ig-like 19
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1896_1982	1	6621	Domain	Note=Ig-like 19
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	110_202	1	7969	Domain	Note=Ig-like 2
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	110_202	1	6621	Domain	Note=Ig-like 2
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	1987_2071	1	7969	Domain	Note=Ig-like 20
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	1987_2071	1	6621	Domain	Note=Ig-like 20
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	2077_2162	1	7969	Domain	Note=Ig-like 21
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	2077_2162	1	6621	Domain	Note=Ig-like 21
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	2165_2249	1	7969	Domain	Note=Ig-like 22
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	2165_2249	1	6621	Domain	Note=Ig-like 22
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	2289_2380	1	7969	Domain	Note=Ig-like 23
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	2289_2380	1	6621	Domain	Note=Ig-like 23
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	2468_2559	1	7969	Domain	Note=Ig-like 24
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	2468_2559	1	6621	Domain	Note=Ig-like 24
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	2564_2643	1	7969	Domain	Note=Ig-like 25
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	2564_2643	1	6621	Domain	Note=Ig-like 25
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	2646_2730	1	7969	Domain	Note=Ig-like 26
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	2646_2730	1	6621	Domain	Note=Ig-like 26
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	2736_2823	1	7969	Domain	Note=Ig-like 27
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	2736_2823	1	6621	Domain	Note=Ig-like 27
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	2826_2908	1	7969	Domain	Note=Ig-like 28
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	2826_2908	1	6621	Domain	Note=Ig-like 28
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	2920_2999	1	7969	Domain	Note=Ig-like 29
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	2920_2999	1	6621	Domain	Note=Ig-like 29
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	236_322	1	7969	Domain	Note=Ig-like 3
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	236_322	1	6621	Domain	Note=Ig-like 3
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3003_3092	1	7969	Domain	Note=Ig-like 30
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3003_3092	1	6621	Domain	Note=Ig-like 30
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3095_3183	1	7969	Domain	Note=Ig-like 31
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3095_3183	1	6621	Domain	Note=Ig-like 31
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3184_3268	1	7969	Domain	Note=Ig-like 32
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3184_3268	1	6621	Domain	Note=Ig-like 32
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3273_3356	1	7969	Domain	Note=Ig-like 33
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3273_3356	1	6621	Domain	Note=Ig-like 33
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3359_3444	1	7969	Domain	Note=Ig-like 34
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3359_3444	1	6621	Domain	Note=Ig-like 34
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3449_3532	1	7969	Domain	Note=Ig-like 35
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3449_3532	1	6621	Domain	Note=Ig-like 35
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3537_3620	1	7969	Domain	Note=Ig-like 36
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3537_3620	1	6621	Domain	Note=Ig-like 36
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3625_3708	1	7969	Domain	Note=Ig-like 37
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3625_3708	1	6621	Domain	Note=Ig-like 37
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3713_3796	1	7969	Domain	Note=Ig-like 38
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3713_3796	1	6621	Domain	Note=Ig-like 38
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3801_3884	1	7969	Domain	Note=Ig-like 39
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3801_3884	1	6621	Domain	Note=Ig-like 39
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	331_414	1	7969	Domain	Note=Ig-like 4
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	331_414	1	6621	Domain	Note=Ig-like 4
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3890_3973	1	7969	Domain	Note=Ig-like 40
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3890_3973	1	6621	Domain	Note=Ig-like 40
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	3978_4062	1	7969	Domain	Note=Ig-like 41
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	3978_4062	1	6621	Domain	Note=Ig-like 41
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	4068_4160	1	7969	Domain	Note=Ig-like 42
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	4068_4160	1	6621	Domain	Note=Ig-like 42
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	4171_4239	1	7969	Domain	Note=Ig-like 43
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	4171_4239	1	6621	Domain	Note=Ig-like 43
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	4248_4337	1	7969	Domain	Note=Ig-like 44
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	4248_4337	1	6621	Domain	Note=Ig-like 44
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	4340_4427	1	7969	Domain	Note=Ig-like 45
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	4340_4427	1	6621	Domain	Note=Ig-like 45
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	4430_4518	1	7969	Domain	Note=Ig-like 46
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	4430_4518	1	6621	Domain	Note=Ig-like 46
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	4624_4714	1	7969	Domain	Note=Ig-like 47
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	4624_4714	1	6621	Domain	Note=Ig-like 47
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	4898_4989	1	7969	Domain	Note=Ig-like 48
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	4898_4989	1	6621	Domain	Note=Ig-like 48
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	5126_5215	1	7969	Domain	Note=Ig-like 49
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	5126_5215	1	6621	Domain	Note=Ig-like 49
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	420_508	1	7969	Domain	Note=Ig-like 5
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	420_508	1	6621	Domain	Note=Ig-like 5
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	5260_5349	1	7969	Domain	Note=Ig-like 50
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	5260_5349	1	6621	Domain	Note=Ig-like 50
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	5371_5467	1	7969	Domain	Note=Ig-like 51
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	5371_5467	1	6621	Domain	Note=Ig-like 51
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	619_698	1	7969	Domain	Note=Ig-like 6
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	619_698	1	6621	Domain	Note=Ig-like 6
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	701_790	1	7969	Domain	Note=Ig-like 7
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	701_790	1	6621	Domain	Note=Ig-like 7
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	798_884	1	7969	Domain	Note=Ig-like 8
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	798_884	1	6621	Domain	Note=Ig-like 8
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	886_977	1	7969	Domain	Note=Ig-like 9
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	886_977	1	6621	Domain	Note=Ig-like 9
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	105	4872_4901	1	7969	Domain	Note=IQ;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00116
Hgene	OBSCN	228524827	KCNK2	215368296	ENST00000284548	65	81	4872_4901	1	6621	Domain	Note=IQ;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00116

- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt).

Partner

Hgeneene

Hbp

Tgeneene

Tbp

ENST

BPexon

TotalExon

Protein feature loci

BPloci

TotalLen

Feature

Note

Top

Kinase Fusion Protein Structures

CIF files of the predicted kinase fusion proteins
* Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format.

Kinase Fusion protein CIF link (fusion AA seq ID in KinaseFusionDB)	Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	AA seq	Len(AA seq)
PDB file >>>HKFP_272_OBSCN_KCNK2	ENST00000284548	ENST00000391895	OBSCN	chr1	228524827	KCNK2	chr1	215368296	MDQPQFSGAPRFLTRPKAFVVSVGKDATLSCQIVGNPTPQVSWEKDQQPVAAGARFRLAQDGDLYRLTILDLALGDSGQYVCRARNAIGE AFAAVGLQVDAEAACAEQAPHFLLRPTSIRVREGSEATFRCRVGGSPRPAVSWSKDGRRLGEPDGPRVRVEELGEASALRIRAARPRDGG TYEVRAENPLGAASAAAALVVDSDAADTASRPGTSTAALLAHLQRRREAMRAEGAPASPPSTGTRTCTVTEGKHARLSCYVTGEPKPETV WKKDGQLVTEGRRHVVYEDAQENFVLKILFCKQSDRGLYTCTASNLVGQTYSSVLVVVREPAVPFKKRLQDLEVREKESATFLCEVPQPS TEAAWFKEETRLWASAKYGIEEEGTERRLTVRNVSADDDAVYICETPEGSRTVAELAVQGNLLRKLPRKTAVRVGDTAMFCVELAVPVGP VHWLRNQEEVVAGGRVAISAEGTRHTLTISQCCLEDVGQVAFMAGDCQTSTQFCVSAPRKPPLQPPVDPVVKARMESSVILSWSPPPHGE RPVTIDGYLVEKKKLGTYTWIRCHEAEWVATPELTVADVAEEGNFQFRVSALNSFGQSPYLEFPGTVHLAPKLAVRTPLKAVQAVEGGEV TFSVDLTVASAGEWFLDGQALKASSVYEIHCDRTRHTLTIREVPASLHGAQLKFVANGIESSIRMEVRAAPGLTANKPPAAAAREVLARL HEEAQLLAELSDQAAAVTWLKDGRTLSPGPKYEVQASAGRRVLLVRDVARDDAGLYECVSRGGRIAYQLSVQGLARFLHKDMAGSCVDAV AGGPAQFECETSEAHVHVHWYKDGMELGHSGERFLQEDVGTRHRLVAATVTRQDEGTYSCRVGEDSVDFRLRVSEPKVVFAKEQLARRKL QAEAGASATLSCEVAQAQTEVTWYKDGKKLSSSSKVCMEATGCTRRLVVQQAGQADAGEYSCEAGGQRLSFHLDVKEPKVVFAKDQVAHS EVQAEAGASATLSCEVAQAQTEVMWYKDGKKLSSSLKVHVEAKGCRRRLVVQQAGKTDAGDYSCEARGQRVSFRLHITEPKMMFAKEQSV HNEVQAEAGASAMLSCEVAQAQTEVTWYKDGKKLSSSSKVGMEVKGCTRRLVLPQAGKADAGEYSCEAGGQRVSFHLHITEPKGVFAKEQ SVHNEVQAEAGTTAMLSCEVAQPQTEVTWYKDGKKLSSSSKVRMEVKGCTRRLVVQQVGKADAGEYSCEAGGQRVSFQLHITEPKAVFAK EQLVHNEVRTEAGASATLSCEVAQAQTEVTWYKDGKKLSSSSKVRIEAAGCMRQLVVQQAGQADAGEYTCEAGGQRLSFHLDVSEPKAVF AKEQLAHRKVQAEAGAIATLSCEVAQAQTEVTWYKDGKKLSSSSKVRMEAVGCTRRLVVQQACQADTGEYSCEAGGQRLSFSLDVAEPKV VFAKEQPVHREVQAQAGASTTLSCEVAQAQTEVMWYKDGKKLSFSSKVRMEAVGCTRRLVVQQAGQAVAGEYSCEAGSQRLSFHLHVAEP KAVFAKEQPASREVQAEAGTSATLSCEVAQAQTEVTWYKDGKKLSSSSKVRMEAVGCTRRLVVQEAGQADAGEYSCKAGDQRLSFHLHVA EPKVVFAKEQPAHREVQAEAGASATLSCEVAQAQTEVTWYKDGKKLSSSSKVRVEAVGCTRRLVVQQAGQAEAGEYSCEAGGQQLSFRLQ VAELEPQISERPCRREPLVVKEHEDIILTATLATPSAATVTWLKDGVEIRRSKRHETASQGDTHTLTVHGAQVLDSAIYSCRVGAEGQDF PVQVEEVAAKFCRLLEPVCGELGGTVTLACELSPACAEVVWRCGNTQLRVGKRFQMVAEGPVRSLTVLGLRAEDAGEYVCESRDDHTSAQ LTVSVPRVVKFMSGLSTVVAEEGGEATFQCVVSPSDVAVVWFRDGALLQPSEKFAISQSGASHSLTISDLVLEDAGQITVEAEGASSSAA LRVREAPVLFKKKLEPQTVEERSSVTLEVELTRPWPELRWTRNATALAPGKNVEIHAEGARHRLVLHNVGFADRGFFGCETPDDKTQAKL TVEMRQVRLVRGLQAVEAREQGTATMEVQLSHADVDGSWTRDGLRFQQGPTCHLAVRGPMHTLTLSGLRPEDSGLMVFKAEGVHTSARLV VTELPVSFSRPLQDVVTTEKEKVTLECELSRPNVDVRWLKDGVELRAGKTMAIAAQGACRSLTIYRCEFADQGVYVCDAHDAQSSASVKV QGRTYTLIYRRVLAEDAGEIQFVAENAESRAQLRVKELPVTLVRPLRDKIAMEKHRGVLECQVSRASAQVRWFKGSQELQPGPKYELVSD GLYRKLIISDVHAEDEDTYTCDAGDVKTSAQFFVEEQSITIVRGLQDVTVMEPAPAWFECETSIPSVRPPKWLLGKTVLQAGGNVGLEQE GTVHRLMLRRTCSTMTGPVHFTVGKSRSSARLVVSDIPVVLTRPLEPKTGRELQSVVLSCDFRPAPKAVQWYKDDTPLSPSEKFKMSLEG QMAELRILRLMPADAGVYRCQAGSAHSSTEVTVEAREVTVTGPLQDAEATEEGWASFSCELSHEDEEVEWSLNGMPLYNDSFHEISHKGR RHTLVLKSIQRADAGIVRASSLKVSTSARLEVRVKPVVFLKALDDLSAEERGTLALQCEVSDPEAHVVWRKDGVQLGPSDKYDFLHTAGT RGLVVHDVSPEDAGLYTCHVGSEETRARVRVHDLHVGITKRLKTMEVLEGESCSFECVLSHESASDPAMWTVGGKTVGSSSRFQATRQGR KYILVVREAAPSDAGEVVFSVRGLTSKASLIVRERPAAIIKPLEDQWVAPGEDVELRCELSRAGTPVHWLKDRKAIRKSQKYDVVCEGTM AMLVIRGASLKDAGEYTCEVEASKSTASLHVEEKANCFTEELTNLQVEEKGTAVFTCKTEHPAATVTWRKGLLELRASGKHQPSQEGLTL RLTISALEKADSDTYTCDIGQAQSRAQLLVQGRRVHIIEDLEDVDVQEGSSATFRCRISPANYEPVHWFLDKTPLHANELNEIDAQPGGY HVLTLRQLALKDSGTIYFEAGDQRASAALRVTEKPSVFSRELTDATITEGEDLTLVCETSTCDIPVCWTKDGKTLRGSARCQLSHEGHRA QLLITGATLQDSGRYKCEAGGACSSSIVRVHARPVRFQEALKDLEVLEGGAATLRCVLSSVAAPVKWCYGNNVLRPGDKYSLRQEGAMLE LVVRNLRPQDSGRYSCSFGDQTTSATLTVTALPAQFIGKLRNKEATEGATATLRCELSKAAPVEWRKGSETLRDGDRYCLRQDGAMCELQ IRGLAMVDAAEYSCVCGEERTSASLTIRPMPAHFIGRLRHQESIEGATATLRCELSKAAPVEWRKGRESLRDGDRHSLRQDGAVCELQIC GLAVADAGEYSCVCGEERTSATLTVKALPAKFTEGLRNEEAVEGATAMLWCELSKVAPVEWRKGPENLRDGDRYILRQEGTRCELQICGL AMADAGEYLCVCGQERTSATLTIRALPARFIEDVKNQEAREGATAVLQCELNSAAPVEWRKGSETLRDGDRYSLRQDGTKCELQIRGLAM ADTGEYSCVCGQERTSAMLTVRALPIKFTEGLRNEEATEGATAVLRCELSKMAPVEWWKGHETLRDGDRHSLRQDGARCELQIRGLVAED AGEYLCMCGKERTSAMLTVRAMPSKFIEGLRNEEATEGDTATLWCELSKAAPVEWRKGHETLRDGDRHSLRQDGSRCELQIRGLAVVDAG EYSCVCGQERTSATLTVRALPARFIEDVKNQEAREGATAVLQCELSKAAPVEWRKGSETLRGGDRYSLRQDGTRCELQIHGLSVADTGEY SCVCGQERTSATLTVRAPQPVFREPLQSLQAEEGSTATLQCELSEPTATVVWSKGGLQLQANGRREPRLQGCTAELVLQDLQREDTGEYT CTCGSQATSATLTVTAAPVRFLRELQHQEVDEGGTAHLCCELSRAGASVEWRKGSLQLFPCAKYQMVQDGAAAELLVRGVEQEDAGDYTC DTGHTQSMASLSVRVPRPKFKTRLQSLEQETGDIARLCCQLSDAESGAVVQWLKEGVELHAGPKYEMRSQGATRELLIHQLEAKDTGEYA CVTGGQKTAASLRVTEPEVTIVRGLVDAEVTADEDVEFSCEVSRAGATGVQWCLQGLPLQSNEVTEVAVRDGRIHTLRLKGVTPEDAGTV SFHLGNHASSAQLTVRAPEVTILEPLQDVQLSEGQDASFQCRLSRASGQEARWALGGVPLQANEMNDITVEQGTLHLLTLHKVTLEDAGT VSFHVGTCSSEAQLKVTAKNTVVRGLENVEALEGGEALFECQLSQPEVAAHTWLLDDEPVHTSENAEVVFFENGLRHLLLLKNLRPQDSC RVTFLAGDMVTSAFLTVRGWRLEILEPLKNAAVRAGAQACFTCTLSEAVPVGEASWYINGAAVQPDDSDWTVTADGSHHALLLRSAQPHH AGEVTFACRDAVASARLTVLGLPDPPEDAEVVARSSHTVTLSWAAPMSDGGGGLCGYRVEVKEGATGQWRLCHELVPGPECVVDGLAPGE TYRFRVAAVGPVGAGEPVHLPQTVRLAEPPKPVPPQPSAPESRQVAAGEDVSLELEVVAEAGEVIWHKGMERIQPGGRFEVVSQGRQQML VIKGFTAEDQGEYHCGLAQGSICPAAATFQVALSPASVDEAPQPSLPPEAAQEGDLHLLWEALARKRRMSREPTLDSISELPEEDGRSQR LPQEAEEVAPDLSEGYSTADELARTGDADLSHTSSDDESRAGTPSLVTYLKKAGRPGTSPLASKVGAPAAPSVKPQQQQEPLAAVRPPLG DLSTKDLGDPSMDKAAVKIQAAFKGYKVRKEMKQQEGPMFSHTFGDTEAQVGDALRLECVVASKADVRARWLKDGVELTDGRHHHIDQLG DGTCSLLITGLDRADAGCYTCQVSNKFGQVTHSACVVVSGSESEAESSSGGELDDAFRRAARRLHRLFRTKSPAEVSDEELFLSADEGPA EPEEPADWQTYREDEHFICIRFEALTEARQAVTRFQEMFATLGIGVEIKLVEQGPRRVEMCISKETPAPVVPPEPLPSLLTSDAAPVFLT ELQNQEVQDGYPVSFDCVVTGQPMPSVRWFKDGKLLEEDDHYMINEDQQGGHQLIITAVVPADMGVYRCLAENSMGVSSTKAELRVDLTS TDYDTAADATESSSYFSAQGYLSSREQEGTESTTDEGQLPQVVEELRDLQVAPGTRLAKFQLKVKGYPAPRLYWFKDGQPLTASAHIRMT DKKILHTLEIISVTREDSGQYAAYISNAMGAAYSSARLLVRGPDEPEEKPASDVHEQLVPPRMLERFTPKKVKKGSSITFSVKVEGRPVP TVHWLREEAERGVLWIGPDTPGYTVASSAQQHSLVLLDVGRQHQGTYTCIASNAAGQALCSASLHVSGLPKVEEQEKVKEALISTFLQGT TQAISAQGLETASFADLGGQRKEEPLAAKEALGHLSLAEVGTEEFLQKLTSQITEMVSAKITQGGSDIEYLDFYKPVVWFWILVGLAYFA AVLSMIGDWLRVISKKTKEEVGEFRAHAAEWTANVTAEFKETRRRLSVEIYDKFQRATSIKRKLSAELAGNHNQELTPCRRTLSVNHLTS	5705_OBSCN_KCNK2

Top

Comparison of Fusion Protein Isoforms

Superimpose the 3D Structures Among All Fusion Protein Isoforms
* Download the pdb file and open it from the molstar online viewer.

Comparison of the Secondary Structures of Fusion Protein Isoforms

Top

Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB

OBSCN_KCNK2 does not have any known PDB structures.

Top

pLDDT score distribution

pLDDT score distribution of the predicted fusion protein structures from AlphaFold2
* AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100.
* The blue color at the bottom marks the best active site residues.

Top

Potential Active Site Information

The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite.

Kinase Fusion AA seq ID in KinaseFusionDB

Site score

Size

Dscore

Volume

Exposure

Enclosure

Contact

Phobic

Philic

Balance

Don/Acc

Residues

Top

Ramachandran Plot of Kinase Fusion Protein Structure

Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide.

Top

Virtual Screening Results

Distribution of the average docking score across all approved kinase inhibitors.
Distribution of the number of occurrence across all approved kinase inhibitors.

5'-kinase fusion protein case

3'-kinase fusion protein case

Top

Drug information from DrugBank of the top 20 interacting small molecules.
* The detailed information of individual kinase inhibitors are available in the download page.

Fusion gene name info	Drug	Docking score	Glide g score	Glide energy
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Lapatinib	-8.76653	-8.85533	-71.9478
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Brigatinib	-8.18802	-8.20152	-57.0235
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Brigatinib	-8.18802	-8.20152	-57.0235
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Tepotinib	-8.0909	-8.092	-62.6049
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Tepotinib	-8.0854	-8.0865	-62.938
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Pralsetinib	-7.97359	-8.06509	-60.0321
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Dacomitinib	-7.89737	-8.00637	-56.6179
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Sorafenib	-7.889589999999999	-7.901689999999999	-54.1388
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Sorafenib	-7.889589999999999	-7.901689999999999	-54.1388
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Avapritinib	-7.865539999999999	-8.663039999999999	-61.9025
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Avapritinib	-7.865539999999999	-8.663039999999999	-61.9025
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Avapritinib	-7.865539999999999	-8.663039999999999	-61.9025
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Avapritinib	-7.865539999999999	-8.663039999999999	-61.9025
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Palbociclib	-7.840389999999999	-8.24729	-63.2132
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Palbociclib	-7.840389999999999	-8.24729	-63.2132
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Trilaciclib	-7.782019999999999	-7.9168199999999995	-52.4613
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Trilaciclib	-7.782019999999999	-7.9168199999999995	-52.4613
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Trilaciclib	-7.782019999999999	-7.9168199999999995	-52.4613
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Trilaciclib	-7.782019999999999	-7.9168199999999995	-52.4613
318_OBSCN_KCNK2-DOCK_HTVS_1-001	Avapritinib	-7.769360000000001	-8.56686	-61.028

Top

Kinase-Substrate Information of OBSCN_KCNK2

Phosphorylation target of the kinase
(phosphosite, 03-17-2024)

Kinase

Kinase UniProt Acc

Kinase species

Substrate

Substrate UniProt Acc

Substrate phosphorylated residues

Substrate phosphorylated sites (+/-7AA)

Domain

Biological Network Integration of This Kinase and Substrates
(GeneMANIA website)

Enriched GO biological processes of the phosphorylation target genes of the kinase

Kinase

GOID

GO term

P.adjust

Top

Related Drugs to OBSCN_KCNK2

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Distribution of the number of studies mentioning OBSCN-KCNK2 and kinase inhibitors the PubMed Abstract (04-01-2024)

Fusion gene - drug pair 1

Fusion gene - drug pair 2

PMID

Publication date

DOI

Study title

Top

Related Diseases to OBSCN_KCNK2

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Related diseases from the literature mentioned this fusion gene and drug.
(PubMed, 04-01-2024)

MeSH ID

MeSH term

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

Top

Clinical Trials of the Found Drugs/Small Molecules

Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024)

Clinical Trials from clinicaltrials.gov (06-17-2024)

Fusion Gene

Kinase Inhibitor

NCT ID

Study Status

Phases

Disease

# Enrolment

Date